Contraceptive use of depot medroxyprogesterone acetate or norethisterone oenanthate was associated with increased inflammation in the female genital tract. Such inflammation is associated with increased HIV target cell availability and the likelihood of an increased risk of HIV acquisition, which is an ongoing concern for users of these contraceptives. The Evidence for Contraceptive Options and HIV Outcomes (ECHO) consortium is conducting a randomized clinical trial to define the role of hormonal contraception in HIV acquisition.
Injectable progestin-only contraception is associated with increased levels of pro-inflammatory cytokines in the female genital tract
Written By
Deese J, Masson L, Miller W, Cohen M, Morrison C, Wang M, Ahmed K, Agot K, Crucitti T, Abdellati S, Van Damme L.
